Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Кашталап, В. В.

doi:10.15829/1560-4071-2022-5285

Russ J Cardiol

2022

DOI: 10.15829/1560-4071-2022-5285

|View full text |Cite

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

В. В. Кашталап

Abstract: The article presents epidemiological data on the high prevalence of hypertension and dyslipidemia comorbidity in the general population, as well as shows the leading role of these key cardiovascular risk factors in the development of cardiovascular events. At the same time, within the primary prevention, the adherence of patients to the lipid-lowering therapy remains low. Fixed-dose combinations (Lipertans) based on antihypertensive (amlodipine, perindopril) and lipid-lowering drugs (atorvastatin) can signific… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Influence of a new coronavirus infection on the arterial stiffness in patients with hypertension

Avdeeva,

Pavlenko,

Salyamova

et al. 2023

Arter. gipertenz.

View full text Add to dashboard Cite

Objective. The aim of the study was to compare the parameters of lipid profile, arterial stiffness and endothelial function in patients with arterial hypertension (HTN), examined before the COronaVIrus Disease-2019 (COVID-19) pandemic, and patients with HTN who underwent COVID-19.Design and methods. In total, 133 people were included: 72 patients with HTN examined in 2010–2015, 61 patients with HTN who survived after COVID-19. A biochemical blood test was performed to determine the level of glucose, total cholesterol, triglycerides, and high-density lipoprotein cholesterol. The level of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol was calculated. The parameters of arterial stiffness were assessed using volume sphygmography, endothelial function was determined based on the values obtained in the sample with post-occlusive reactive hyperemia.Results. According to the results of a biochemical blood test, a significantly higher level of total cholesterol and non-high-density lipoprotein cholesterol was noted in patients with HTN who underwent COVID-19. In the compared groups, comparable indicators of endothelial function were registered with post-occlusive reactive hyperemia. At the same time, according to volume sphygmography, the highest values of arterial stiffness indicators (pulse wave velocity in the aorta, pulse wave velocity in elastic arteries, cardio-ankle vascular index on the right and left) were found in patients with HTN who had undergone COVID-19. A univariate regression analysis was carried out, which confirmed a significant negative effect of the transferred COVID-19 on the parameters of arterial stiffness.Conclusions. Patients with HTN in the post-COVID period represent a particularly vulnerable cohort of the population in terms of the risk of developing and progressing cardiovascular pathology, including vascular events. The inclusion of volume sphygmography in the list of examinations will probably allow early detection of an increase in arterial stiffness with subsequent drug correction.

show abstract

Influence of a new coronavirus infection on the arterial stiffness in patients with hypertension

Avdeeva,

Pavlenko,

Salyamova

et al. 2023

Arter. gipertenz.

View full text Add to dashboard Cite

show abstract

The effectiveness of a multi‑target therapy polypill in patients with hypertension and dyslipidemia after novel coronavirus infection

Oleinikov,

Avdeeva,

Pavlenko

et al. 2024

Arter. gipertenz.

View full text Add to dashboard Cite

Objective. The aim is to study antihypertensive and lipid-lowering effects of polypill therapy in patients with arterial hypertension (HTN) grade 1–2 and dyslipidemia, who had a novel coronavirus infection. Design and methods. We enrolled 65 patients with HTN and dyslipidemia after COronaVIrus Disease-2019, of which 60 people (92,3 %) completed observation. During 24 weeks patients took polypill therapy, including indapamide, perindopril and rosuvastatin. Office blood pressure (BP) measurements using the Korotkov method and 24-hour ambulatory BP monitoring (ABPM) were performed; level of total cholesterol, triglycerides, high density lipoprotein cholesterol were assessed. Low-density lipoprotein cholesterol (LDL–C) and non-high-density lipoprotein cholesterol levels were calculated. Results. After 24 weeks of polypill therapy 54 patients (90 %) reached target BP levels. According to 24-hour ABPM data, there was a significant decrease in the average daily, average day and night BP values, reduction in blood pressure load and BP variability (p < 0,001). By the end of treatment, there was an increase in the number of patients with normal daily profile (dipper) (р < 0,05). After 24 weeks, an improvement of lipid profile indicators was recorded, target level of LDL–C was achieved in 28 (84,8 %) patients at high risk and 15 (55,6 %) patients at very high risk. Chances of simultaneous achievement of target values for BP and LDL–C in the high risk group were 4 times higher than in the very high risk group (odds ratio 4,2 [95 % confidence interval 1,3–13,4]; p = 0,028). Conclusions. According to 24-hour ABPM data, 24-week polypill therapy including indapamide, perindopril and rosuvastatin leads to a significant reduction in average daily BP values and contributes to the normalization of the daily profile. After 6-months therapy, target BP and LDL–C levels were achieved in 68,3 % patients with HTN and dyslipidemia who have had COVID-19.

show abstract

Fixed triple combination of amlodipine, perindopril and atorvastatin in the focus of cardiovascular effectiveness and safety

Kuchmin,

Sveklina,

Oktysyuk

et al. 2023

Evrazijskij kardiologičeskij žurnal

View full text Add to dashboard Cite

The review outlines modern concepts of the relevance of fixed-dose combination therapy comprising angiotensin-converting enzyme inhibitor and dihydropyridine calcium channel antagonist as an antihypertensive component with the HMG-CoA reductase inhibitor when treating hypertensive patients. We have identified the realms of its possible clinical use taking into consideration the comorbidity peculiarities. In addition, we provide main features of the current drugs’ clinical pharmacodynamics and outline their role in real clinical practice. Nevertheless the emphasis was placed on the modern single-pill combination of amlodipin, atorvastatin and perindopril. We concisely report the results data collected from the large, randomized, double-blind major clinical trials regarding the effectiveness of single pill combination of amlodipine, atorvastatin and perindopril , primary focusing on their cardioprotective features and overall safety profile.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Therapy for hypertension and dyslipidemia: potential of Lipertans (on the example of a clinical observation)

Cited by 3 publications

References 43 publications

Influence of a new coronavirus infection on the arterial stiffness in patients with hypertension

Influence of a new coronavirus infection on the arterial stiffness in patients with hypertension

The effectiveness of a multi‑target therapy polypill in patients with hypertension and dyslipidemia after novel coronavirus infection

Fixed triple combination of amlodipine, perindopril and atorvastatin in the focus of cardiovascular effectiveness and safety

Contact Info

Product

Resources

About